Meriwether Wealth & Planning’s Sarepta Therapeutics SRPT Stock Holding History

Meriwether Wealth & Planning’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$29.6K	Buy	+1,625	New	+$30.4K	0.01%	314

Other funds holding SRPT

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

QFA

Quattro Financial Advisors The Woodlands, Texas $483M AUM 11.42% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

CFS

CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return

Meriwether Wealth & Planning's SRPT Position: Q3 2026 in Review

Meriwether Wealth & Planning opened a new position in Sarepta Therapeutics (SRPT) in Q3 2026: 1,625 shares worth $29.6K. The stake represents 0.01% of the portfolio and ranks #314 among its holdings.

20 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

Meriwether Wealth & Planning held 1,625 shares of Sarepta Therapeutics worth $29.6K as of Q3 2026.
Sarepta Therapeutics was a new Meriwether Wealth & Planning position in Q3 2026.
Sarepta Therapeutics made up 0.01% of Meriwether Wealth & Planning's portfolio in Q3 2026, its #314 holding.
20 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Meriwether Wealth & Planning's 13F filing for Q3 2026, filed 13 Oct 2026.